We showed that MMP1 levels, as surrogate markers for the response to treatment, in PAR1CAR-T-cell-treated tumor sections were significantly oriented downward compared to those treated with mock-transduced T cells, non-transduced T cells, and PBS. Here, MMP1 is linked to neoplasm.